Allspring Global Investments
BTAI icon

Allspring Global Investments’s BioXcel Therapeutics BTAI Stock Holding History

Allspring Global Investments’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-278
Closed -$11.2K – 2288
2023
Q3 		$11.2K Buy
278
+175
+170% +$17.7K ﹤0.01% 2599
2023
Q2 		$10.9K Sell
103
-2,979
-97% -$992K ﹤0.01% 2531
2023
Q1 		$920K Buy
+3,082
New +$1.32M ﹤0.01% 1434

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Allspring Global Investments's BTAI Position: Q4 2023 in Review

Allspring Global Investments sold out of BioXcel Therapeutics (BTAI) in Q4 2023, closing a stake of 278 shares — an estimated $11.2K sold.

Allspring Global Investments first reported a position in BTAI in Q1 2023 and held it in 3 quarters. The position peaked at $920K in Q1 2023. 73 funds tracked by Wall St. Rank hold BTAI as of Q4 2023.

  • Allspring Global Investments reported no remaining BioXcel Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Allspring Global Investments sold 278 BioXcel Therapeutics shares in Q4 2023, an estimated $11.2K.
  • Allspring Global Investments first reported a position in BioXcel Therapeutics in Q1 2023 and held it in 3 quarters.
  • Allspring Global Investments's BioXcel Therapeutics position peaked at $920K in Q1 2023.
  • 73 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2023.

Based on Allspring Global Investments's 13F filing for Q4 2023, filed 25 Jan 2024.